- Johnson Controls International PLC (NYSE:JCI) reported fourth-quarter FY22 sales growth of 5% year-on-year to $6.73 billion, marginally missing the consensus of $6.75 billion.
- Gross profit rose 4.7% Y/Y to $2.2 billion. Adjusted segment EBITA was $1.1 billion, and adjusted segment EBITA margin was 16.5%.
- Adjusted EPS of $0.99 beat the analyst consensus of $0.98.
- Johnson Controls generated a Q4 operating cash flow of $1.2 billion and held $2.03 billion in cash and equivalents as of September 30, 2022.
- Inventories at the end of the quarter were $2.5 billion, a 22% Y/Y rise.
- Outlook: Johnson sees Q1 adjusted EPS of $0.65 – $0.67, above the consensus of $0.63. Organic revenue growth of low double-digit year-over-year.
- The company sees FY23 adjusted EPS of $3.20 – $3.60, against the consensus of $3.52. Organic revenue growth of high single-digits to low double-digits year-over year.
- Price Action: JCI shares are trading higher by 6.39% at $60.76 on the last check Thursday.
- Photo Via Company
Immatics Reported Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy With ACTengine IMA203 TCR-T Targeting PRAME
Immatics N.V. (NASDAQ:IMTX, "Immatics"))) today announced an interim clinical data update for 11 patients with recurrent and/or refractory solid cancers treated with ACTengine® IMA203 TCR-T monotherapy in the ongoing Phase 1b dose expansion Cohort A.
